Two-stage designs for Phase 2 dose-finding trials

Statistics in Medicine

Volumn 31, Issue 24, 2012, Pages 2872-2881

  Ivanova, Anastasia ^a   Xiao, Changfu ^a   Tymofyeyev, Yevgen ^b  

^a The University of North Carolina at Chapel Hill   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dose ranging; Maximum dose; Minimum effective dose; Phase 2 trials; Two stage designs

Indexed keywords

ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DOSE; DRUG DOSE SEQUENCE; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; MINIMUM EFFECTIVE DOSE; NULL HYPOTHESIS; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; SAMPLE SIZE; SEQUENTIAL ANALYSIS; SIMULATION; STATISTICAL DISTRIBUTION; STUDY DESIGN; TWO STAGE DESIGN;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 84867330178     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5365     Document Type: Article

References (18)

1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline: E4 dose-response information to support drug registration. Current step 4 version, March 10, 1994. Available at: http://www.ich.org/LOB/media/MEDIA480.pdf.
2. Dragalin V, Fedorov V. Adaptive designs for dose-finding based on efficacy-toxicity response. Journal of Statistical Planning and Inference 2006; 136:1800-1823.
3. Berry DA, Müller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M. Adaptive Bayesian designs for dose-ranging drug trials. In Case Studies in Bayesian Statistics V, Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M (eds). Springer-Verlag: New York, 2001; 99-181.
4. Ivanova A, Liu K, Snyder E, Snavely D. An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose finding study. Statistics in Medicine 2009; 28:2941-2951.
5. Smith MK, Jones I, Morris MF, Grieve AP, Tan K. Implementation of a Bayesian adaptive design in proof of concept study. Pharmaceutical Statistics 2006; 5:39-50.
6. Ivanova A, Bolognese J, Perevozskaya I. Adaptive design based on t-statistic for dose-response trials. Statistics in Medicine 2008; 27:1581-1592.
7. Miller F, Guilbaud O, Dette H. Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve. Journal of Biopharmaceutical Statistics 2007; 17:1097-1115.
8. Dragalin V, Fedorov V, Wu Y. Adaptive designs for selecting drug combinations based on efficacy-toxicity response. Journal of Statistical Planning and Inference 2008; 138:352-373.
9. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Chapman and Hall: London, 1995.
10. Dunson D, Neelon B. Bayesian inference on order-constrained parameters in generalized linear models. Biometrics 2003; 59:286-295.
11. Gunn L, Dunson D. A transformation approach for incorporating monotone or unimodal constraints. Biostatistics 2005; 6(3):434-449.
12. Robertson T, Wright FT, Dykstra RL. Ordered Restricted Statistical Inference. Wiley: New York, 1988.
13. Koenig F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625.
14. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24:3697-3714.
15. Dykstra RL, Robertson T. An Algorithm for isotonic regression for two or more independent variables. Annals of Statistics 1982; 10:708-716.
16. Thall PF, Inoue LYT, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics 2002; 58:560-568.
17. Thompson WR. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. Biometrika 1933; 25:285-294.
18. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005; 61:738-748.